Cagrilintide + Semaglutide Dosage, Reconstitution & Mixing Trends

Explore cagrilintide + semaglutide calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized cagrilintide + semaglutide calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What Cagrilintide + Semaglutide Is

Cagrilintide + Semaglutide (CagriSema) is a research-grade blend of an amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide), most often sourced for weight-management and metabolic research. Novo Nordisk's pharmaceutical version completed Phase 3 obesity trials but is not yet FDA-approved. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]

CagriSema combines two complementary appetite-regulating pathways in a single weekly subcutaneous injection. The semaglutide arm produces standard GLP-1 effects (slowed gastric emptying, glucose-dependent insulin release, hypothalamic appetite suppression). The cagrilintide arm activates amylin receptors and calcitonin-receptor heterodimers in the area postrema and hypothalamus, reinforcing satiety and slowing gastric emptying through a complementary brainstem-mediated pathway. The combination is rationalised by amylin and GLP-1 working through non-overlapping receptor systems.

REDEFINE-1 reported mean weight loss of approximately 22.7% at 68 weeks on the highest-dose CagriSema arm versus 16.1% on semaglutide alone and 11.8% on cagrilintide alone, in adults with obesity but without T2D — confirming meaningful additive benefit over either component, though the headline figure undershot Novo's pre-trial expectation of ~25%.[1] REDEFINE-2 reported approximately 13.7% mean weight loss at 68 weeks in adults with obesity and T2D, with A1C reductions in the 1.8–2.0% range.[2] A Phase 2 study (Frias et al., Lancet 2021) established the dose-response profile.[3] See also the standalone Cagrilintide and Semaglutide entries for component-level detail.

Not FDA- or EMA-approved. REDEFINE-1 and REDEFINE-2 Phase 3 obesity trials read out 2024–2025; regulatory filings in preparation. Research-grade material elsewhere.

Cagrilintide + Semaglutide Research Sources

Cagrilintide + Semaglutide Dosing Context

Cagrilintide + Semaglutide has a reported half-life of ~7 days (both components). The pharmacokinetic reference models an interval of once weekly; this is not a measured community cadence or a dosing recommendation. Both parts are long-acting (about a week each), so once-weekly dosing builds to a steady level over roughly 5 weeks. Pharmacokinetic source: Novo Nordisk CagriSema trials (cagrilintide + semaglutide). It is catalogued under Weight Loss on WPA.

Cagrilintide + Semaglutide Community Calculator Data

48 Cagrilintide + Semaglutide reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

Cagrilintide + Semaglutide (CagriSema) Research Background and Calculator Data

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.